Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Two Arm, Multicenter, Randomized, Parallel Group, Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies

NCT03973775 is registered in ClinicalTrials.gov with Saptalis Pharmaceuticals LLC as lead sponsor.

NCT NCT03973775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03973775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Two Arm, Multicenter, Randomized, Parallel Group, Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies
Lead sponsor
Saptalis Pharmaceuticals LLC
Phase
Phase 3
Overall status
Completed
Start date
April 10, 2018
Completion date
December 6, 2018
Enrollment
126 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

scabies